期刊文献+

两种二线方案治疗老年弥漫大B细胞淋巴瘤的临床观察 预览

Clinical observation on two kinds of second-line treatment regimens for elderly diffuse large B-cell lymphoma
在线阅读 下载PDF
分享 导出
摘要 目的探讨两种二线方案治疗老年弥漫大B细胞淋巴瘤(DLBCL)的临床效果。方法选取2010年7月至2018年7月本院收治的老年DLBCL患者96例为研究对象,回顾性分析患者临床资料,将采用R-ICE治疗的患者纳入对照组(n=48),采用R-GEMOX治疗的患者纳入观察组(n=48),对两组治疗效果进行对比分析。结果观察组治疗有效率97.92%略高于对照组93.75%,但差异无统计学意义(P>0.05);治疗后两组FOXP1、Livin表达阳性率均降低,且观察组FOXP1、Livin表达阳性率显著低于对照组(P<0.05);观察组不良反应发生率10.42%显著低于对照组27.08%(P<0.05)。结论R-GEMOX治疗DLBCL疗效略优于R-ICE方案,可显著降低FOXP1、Livin表达阳性率及不良反应发生率,值得在临床上推广应用。 Objective To explore the clinical effect of two kinds of second-line treatment regimens for elderly diffuse large B-cell lymphoma (DLBCL). Methods A total of 96 elderly patients with DLBCL who were admitted to our hospital from July 2010 to July 2018 were selected as the subjects. The clinical data of the patients were retrospectively analyzed. Patients treated with R-ICE were included in control group (n=48), while those treated with R-GEMOX were included in observation group (n=48). The treatment effects were compared between the two groups. Results The response rate of the observation group was slightly higher than that of the control group (97.92% vs.93.75%)(P>0.05). The positive expression rates of FOXP1 and Livin in both groups decreased after treatment, and the positive expression rates of FOXP1 and Livin in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (10.42% vs.27.08%)(P<0.05). Conclusion The curative effect of R-GEMOX is better than R-ICE in the treatment of DLBCL. The former can significantly reduce the positive expression rates of FOXP1 and Livin and the incidence of adverse reactions.
作者 陈秀容 蔡勇君 杨瑜 吴晖 何鸿鸣 陈道光 陈英 林剑扬 陈宁斌 郑艳彬 邹思平 王杰松 王畅 Chen Xiurong;Cai Yongjun;Yang Yu;Wu Hui;He Hongming;Chen Daoguang;Chen Ying;Lin Jianyang;Chen Ningbin;Zheng Yanbin;Zou Siping;Wang Jiesong;Wang Chang(Department of Medical Oncology, Fujian Cancer Hospital, Affiliated Cancer Hospital of Fujian Medical University, Fuzhou 350014, China)
出处 《国际医药卫生导报》 2019年第6期903-905,共3页 International Medicine & Health Guidance News
关键词 R-ICE R-GEMOX 老年 弥漫大B 细胞淋巴瘤 R-ICE R-GEMOX Elderly Diffuse large B-cell lymphoma
作者简介 通信作者:杨瑜,Email:yangyu901@163.com.
  • 相关文献

参考文献3

二级参考文献38

  • 1程月新,徐卫,李建勇,钱思轩,陆化,吴汉新,陈丽娟.非霍奇金淋巴瘤641例临床分析[J].南京医科大学学报:自然科学版,2006,26(9):837-840. 被引量:13
  • 2Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010,102(3): 83-87. 被引量:1
  • 3Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions [J]. Cancer Control, 2012, 19 (3): 204-213. 被引量:1
  • 4Coiffier B.Diffuse large cell lymphoma [J]. Curr Opin Oncol, 2001, 13(5): 325-334. 被引量:1
  • 5Pfreundschuh M, Kuhnt E, Triimper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open- label randomised study of the MabThera International Trial (MINT) Group [ J ]. Lancet Oncol, 2011,12 ( 11 ): 1013-1022. 被引量:1
  • 6Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B- cell lymphoma (LNH03- 2B): an open- label randomised phase 3 trial [J]. Lancet, 2011, 378(9806):1858-1867. 被引量:1
  • 7Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [J]. N Engl J Med, 1995, 333(23): 1540-1545. 被引量:1
  • 8Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on High- Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non- Hodgkin's Lymphomas: report of the jury [J]. J Clin Oncol,1999, 17( 1 ): 423-429. 被引量:1
  • 9Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell trans- plantation for relapsed or primary refractory diffuse large B-cell lymphoma [ J ]. Blood, 2004, 103 (10): 3684-3688. 被引量:1
  • 10Habermann TM. New developments in the management of diffuse large B-cell lymphoma[J] . Hematology, 2012, 17 Suppl 1: S93-S97. 被引量:1

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈